Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report (Q37954539)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

25 August 2017

Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report (English)

1 reference

Europe PubMed Central

25 August 2017

0 references

1 reference

based on heuristic

inferred from title

0 references

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

25 August 2017

object named as

M Aringer

1

0 references

Winfried B. Graninger

object named as

W Graninger

6

0 references

Gerd-Rüdiger Burmester

3

object named as

G R Burmester

1 reference

Europe PubMed Central

25 August 2017

Christof Specker

0 references

1 reference

ORCID Public Data File 2021

author name string

H Burkhardt

2

1 reference

Europe PubMed Central

25 August 2017

R Fischer-Betz

4

1 reference

Europe PubMed Central

25 August 2017

M Fleck

5

1 reference

Europe PubMed Central

25 August 2017

F Hiepe

7

1 reference

Europe PubMed Central

25 August 2017

A M Jacobi

8

1 reference

Europe PubMed Central

25 August 2017

H J Lakomek

10

1 reference

Europe PubMed Central

25 August 2017

H M Lorenz

11

1 reference

Europe PubMed Central

25 August 2017

B Manger

12

1 reference

Europe PubMed Central

25 August 2017

G Schett

13

1 reference

Europe PubMed Central

25 August 2017

R E Schmidt

14

1 reference

Europe PubMed Central

25 August 2017

M Schneider

15

1 reference

Europe PubMed Central

25 August 2017

H Schulze-Koops

16

1 reference

Europe PubMed Central

25 August 2017

J S Smolen

17

1 reference

Europe PubMed Central

25 August 2017

C Specker

18

1 reference

Europe PubMed Central

25 August 2017

T Stoll

19

1 reference

Europe PubMed Central

25 August 2017

A Strangfeld

20

1 reference

Europe PubMed Central

25 August 2017

H P Tony

21

1 reference

Europe PubMed Central

25 August 2017

P M Villiger

22

1 reference

Europe PubMed Central

25 August 2017

R Voll

23

1 reference

Europe PubMed Central

25 August 2017

T Witte

24

1 reference

Europe PubMed Central

25 August 2017

T Dörner

25

1 reference

Europe PubMed Central

25 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 November 2011

1 reference

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

25 August 2017

21

1 reference

Europe PubMed Central

25 August 2017

4

1 reference

Europe PubMed Central

25 August 2017

386-401

1 reference

Europe PubMed Central

25 August 2017

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Cytokines as therapeutic targets in SLE.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

B-cell-directed therapies for autoimmune disease

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The red wolf remains a wily foe.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

NIH conference. Systemic lupus erythematosus: evolving concepts

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Mortality in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The socioeconomic burden of SLE.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Predictors of major infections in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Immunoadsorption for systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Diagnosis and management of the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The course of anticardiolipin antibody levels under immunoadsorption therapy

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Response of vasculitic peripheral neuropathy to intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Selective immunoadsorption in neurologic complications of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Azathioprine therapy for patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

The treatment of lupus with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Intravenous immunoglobulin therapy and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Autosplenectomy and antiphospholipid antibodies in systemic lupus erythematosus: A pathogenetic relationship?

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

International consensus report on the investigation and management of primary immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Treatment of hemorrhagic lupus pneumonitis with plasmapheresis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Alveolar hemorrhage in systemic lupus erythematosus: presentation and management

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Diffuse alveolar hemorrhage in systemic lupus erythematosus: a single center retrospective study in Taiwan.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab).

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Effects of rituximab on resistant SLE disease including lung involvement.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Guidelines for the diagnosis and treatment of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Apheresis for lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Letter to the Editor

1 reference

https://api.crossref.org/works/10.1177%2F0961203311426569

21 January 2018

Identifiers

10.1177/0961203311426569

1 reference

Europe PubMed Central

25 August 2017

release_dbccaidwnzesxek7637zx7nhpi

1 reference

https://api.fatcat.wiki/v0/release/dbccaidwnzesxek7637zx7nhpi

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37954539&oldid=2088632952"